The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma

被引:2
|
作者
He, Lirui [1 ]
Ren, Dandan [2 ]
Lv, Guoqing [1 ]
Mao, Beibei [2 ]
Wu, Lijia [2 ]
Liu, Xiaoyu [3 ]
Gong, Longlong [2 ]
Liu, Ping [3 ]
机构
[1] Peking Univ, Shenzhen Hosp, Dept Gastrointestinal Surg, Shenzhen, Peoples R China
[2] Genecast Biotechnol Co Ltd, 18 Xihu Rd, Guangzhou 510000, Guangdong, Peoples R China
[3] Cent South Univ, Xiangya Hosp 2, Dept Oncol, 139 Renming Middle Rd, Changsha 410011, Hunan, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 01期
关键词
head and neck squamous cell carcinoma; human papillomavirus; immune infiltration; tumor fusion burden; CANCER; NEOANTIGENS; EPIDEMIOLOGY;
D O I
10.1002/cam4.4890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Recent studies suggest that tumor fusion burden (TFB) is a hallmark of immune infiltration in prostate cancer, the correlation of TFB with immune microenvironment, and genomic patterns in head and neck squamous cell carcinomas (HNSC) remain largely unclear. Methods Gene fusion, genomic, transcriptomic, and clinical data of HNSC patients from the cancer genome atlas (TCGA) database were collected to analyze the correlation of TFB with mutation patterns, tumor immune microenvironment, and survival time in HNSC patients. Results Human papillomavirus (HPV) (-) patients with low TFB exhibited significantly enhanced CD8+ T cells infiltration and cytolysis activity and increased level of interferon-gamma (IL-gamma), human leukocyte antigen (HLA) class I, and chemokines. Moreover, TFB was positively correlated with TP53 mutation, score of gene copy number, and loss of heterozygosity (LOH), as well as the biological progress of epithelial-mesenchymal transition (EMT), metastasis, and stem cell characteristics. Further analysis revealed that HPV (-) HNSC patients with low TFB have a better prognosis. Conclusions Our data revealed the correlation of TFB with tumor immune microenvironment and predictive features for immunotherapy, implying tumors with low TFB may be potential candidates for immunotherapeutic agents. Moreover, the TFB low group had prolonged overall survival (OS) in the HPV (-) HNSC cohort.
引用
收藏
页码:852 / 861
页数:10
相关论文
共 50 条
  • [21] Understanding the tumor microenvironment in head and neck squamous cell carcinoma
    Rad, Habib Sadeghi
    Shiravand, Yavar
    Radfar, Payar
    Ladwa, Rahul
    Perry, Chris
    Han, Xiaoyuan
    Warkiani, Majid Ebrahimi
    Adams, Mark N.
    Hughes, Brett G. M.
    O'Byrne, Ken
    Kulasinghe, Arutha
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022, 11 (06)
  • [22] Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck
    Sandra Schmitz
    Jean-Pascal Machiels
    Current Treatment Options in Oncology, 2016, 17
  • [23] Squamous cell carcinoma of the head and neck in nonsmokers: clinical and biologic characteristics and implications for management
    Lingen, M
    Sturgis, EM
    Kies, MS
    CURRENT OPINION IN ONCOLOGY, 2001, 13 (03) : 176 - 182
  • [24] The characteristics of ctDNA monitoring in head and neck squamous cell carcinoma
    Kogo, Ryunosuke
    Manako, Tomomi
    Iwaya, Takeshi
    Hiraki, Hayato
    Nishizuka, Satoshi
    Idogawa, Masashi
    Tokino, Takashi
    Nakagawa, Takashi
    CANCER SCIENCE, 2023, 114 : 648 - 648
  • [25] Clinical relevance of tumour markers in head and neck squamous cell carcinomas
    Stieber, P
    Wollenberg, B
    Schmitt, UM
    vonJan, N
    Hofmann, K
    FatehMoghadam, A
    TUMORDIAGNOSTIK & THERAPIE, 1996, 17 (04) : 116 - 121
  • [26] Association of Patient and Tumor Characteristics With Outcomes in Young Head and Neck Squamous Cell Carcinoma Patients
    Hsieh, Ronan W.
    Gooding, William E.
    Nilsen, Marci
    Kubik, Mark
    Kelly, Zahra
    Sridharan, Shaum
    Skinner, Heath
    Iheagwara, Uzoma
    Zevallos, Jose P.
    Duvvuri, Umamaheswar
    Kim, Seungwon
    Ferris, Robert L.
    Zandberg, Dan P.
    CLINICAL OTOLARYNGOLOGY, 2025, 50 (01) : 15 - 21
  • [27] Immunologic characteristics of circulating tumor cells in patients with head and neck squamous cell carcinoma.
    Tada, Hiroe
    Takahashi, Hideyuki
    Ishii, Hiroki
    Kuwabara-Yokobori, Yuki
    Ida, Shota
    Shino, Masato
    Chikamatsu, Kazuaki
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 118 - 118
  • [28] The tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of molecular markers
    Hoogsteen, I. J.
    Wijffels, K. I.
    Marres, H. A. M.
    van den Hoogen, F. J. A.
    van der Kogel, A. J.
    Kaanders, J. H. A. M.
    RADIOTHERAPY AND ONCOLOGY, 2007, 82 : S27 - S28
  • [30] Proteomics: Clinical applications for head and neck squamous cell carcinoma
    Yarbrough, Wendell G.
    Slebos, Robbert J. C.
    Liebler, Daniel
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2006, 28 (06): : 549 - 558